a promising future for treating multiple myeloma with bispecific antibodies
Published 2 years ago • 7.7K plays • Length 1:04:12Download video MP4
Download video MP3
Similar videos
-
3:25
what should myeloma patients know about bispecific antibodies?
-
4:26
what are bispecific antibodies?
-
6:35
the benefits of bispecific antibodies for treating multiple myeloma
-
5:44
bispecific antibodies: early side effects
-
57:20
know your myeloma immunotherapy: bispecific antibodies with dr. cesar rodriguez
-
4:45
bispecifics part 2: monoclonal and bispecific antibodies
-
6:17
myeloma made simple: bispecific antibodies made simple | bispecific antibodies for myeloma treatment
-
5:08
what should myeloma patients know about the new immune therapies?
-
23:13
bispecific antibodies in multiple myeloma | dana-farber cancer institute
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
1:26
emerging monoclonal antibodies for the treatment of multiple myeloma
-
3:23
a bright future for multiple myeloma
-
3:22
talquetamab, cevostamab and car-t in the future treatment of myeloma
-
18:39
immunotherapy in myeloma: current strategies and future perspectives
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
5:20
myeloma university | monoclonal antibodies as treatment for multiple myeloma
-
6:15
patrick laroche, asco20: bispecific antibodies in the treatment of multiple myeloma
-
4:16
what is the monoclonal antibody talvey™ (talquetamab)?
-
2:48:35
patient & family webinar: the future is looking bright for myeloma patients!